Takeda: Ovarian Neoplasms trials
The registry lists 11 Ovarian Neoplasms studies with Takeda as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 4Phase 2 7No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsActive, not recruitingNCT06390995Phase 1/2Results posted
- Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian CancerCompletedNCT03759600Phase 2Results posted
- Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian CancerCompletedNCT03759587Phase 2Results posted
- Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian CancerTerminatedNCT02540356Phase 1/2Results posted
- Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid TumorsTerminatedNCT02367352Phase 1Results posted
- Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerCompletedNCT01091428Phase 2Results posted
- MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedNCT00853307Phase 2Results posted
- A Study of Niraparib in Patients With Ovarian Cancer in Clinical PracticeCompletedNCT05021562
- A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South KoreaCompletedNCT04589039
- Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing RegimensWithdrawnNCT00610792Phase 2
- Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2CompletedNCT00034281Phase 1